Human Germline Genome Editing, 10 Years On
Author:
- 8 July 2025
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (2) , 111
Abstract
This Viewpoint discusses human germline genome editing (GGE) in light of changes in the landscape around biomedical technology over the last 10 years, considering ethical, legal, and social issues and in particular whether GGE holds future therapeutic value.Keywords
This publication has 8 references indexed in Scilit:
- The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell DiseaseJAMA, 2024
- Welcoming the Era of Gene Editing in MedicineNew England Journal of Medicine, 2024
- Past, present, and future of CRISPR genome editing technologiesCell, 2024
- A new frontier: FDA approvals for gene therapy in sickle cell diseaseMolecular Therapy, 2024
- CRISPR People2021
- CRISPR/Cas9-mediated gene editing in human tripronuclear zygotesProtein & Cell, 2015
- Embryo engineering alarmScience, 2015
- Don’t edit the human germ lineNature, 2015